Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: health

New sensor could allow MRIs to see molecular-level changes

You’ve seen people sliding into the tube of a magnetic resonance imaging (MRI) machine on your favorite medical drama, or maybe you’ve been inside one yourself, waiting as the noisy scanner makes images of your brain, heart, bones, or other structures, which doctors use to identify injury or disease.

Since the 1970s, MRIs have been important diagnostic tools, combining a magnetic field and radio waves to produce snapshots of the body’s interior without using ionizing radiation, which can create health risks at higher doses. An MRI can typically capture changes in anatomy, but the molecular-level changes that could further aid understanding of disease have been beyond its reach.

Now, in a new article in Science Advances, University of California, Santa Barbara researchers report the invention of a modular, genetically encoded, protein-based sensor that enables MRI machines to visualize molecular activity inside cells—a development that could transform how scientists study cancer, neurodegeneration, and inflammation.

Therapeutic, nasally delivered DNA vaccine fuses two genes to help fight tuberculosis

In a paper published in the Journal of Clinical Investigation, a research team at Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health reports developing a therapeutic intranasal (nose-delivered) DNA vaccine against tuberculosis (TB) that fuses two genes with the goal of directing the immune system to fight drug-tolerant bacterial “persisters” that can survive prolonged antibiotic therapy and contribute to disease relapse.

A scourge for at least the past 6,000 years, TB is estimated by the World Health Organization (WHO) to be a latent, symptom-free infection in about one-quarter of the world’s population, approximately 2 billion people. In 2024 alone, WHO reported that more than 10 million people worldwide developed active TB disease, with 1.2 million deaths recorded. This makes TB the leading cause of death from a single infectious disease.

In recent years, WHO has called for therapeutic vaccines that can be used alongside drug therapies to shorten TB treatment regimens and improve outcomes, particularly because long multidrug courses are difficult to complete, and drug-resistant TB strains continue to emerge. The vaccine described in the new Johns Hopkins study shows promise for meeting that need.

A stiff defense: Physical rigidity of healthy gum tissue found to shield against chronic periodontal inflammation

Periodontitis is a serious chronic inflammatory form of gum disease that affects millions worldwide. It can lead to tooth loss and the destruction of supporting bone. This disease has also been linked to other health problems, including diabetes, respiratory infections, and heart disease, impacting quality of life and increasing health care costs.

Current treatments target bacterial infection and inflammation through nonsurgical therapies, such as scaling and root planing, commonly known as “deep cleaning.” However, they do not repair the gum’s extracellular matrix (ECM), the gingival tissue’s structural support that is damaged by chronic inflammation. Without this foundation, gingival tissue cannot function properly, allowing inflammation to persist and slowing healing.

Now, new research led by Kyle H. Vining and Hardik Makkar of the School of Dental Medicine demonstrates how the physical properties of the gingival tissue impact periodontal health and disease. Their findings are published in Advanced Materials.

Pitfalls and Potential of Dementia Prevention Trials

💬 Editorial by Holly Elser, MD, PhD, and Jonathan Graff-Radford, MD:

Recent randomized clinical trials on dementia prevention highlight several challenges in interpreting lifestyle intervention studies, including practice and Hawthorne effects, modest changes in cognitive outcomes, and heterogeneity in both trial design and participant baseline risk.

The trial by Zhang et al—evaluating aerobic exercise and intensive vascular risk reduction—showed no significant cognitive benefit over 2 years in older adults at elevated risk, underscoring the potential influence of midlife vs late-life intervention timing and the need for longer trials or biomarker-enriched cohorts to better assess dementia prevention strategies.

Dementia prevention is a global public health priority,1,2 with up to 45% of cases potentially attributable to modifiable risk factors over the life course.3 While recent landmark trials, including FINGER, SPRINT MIND, and POINTER, suggest either single-or multidomain lifestyle interventions can improve cognitive outcomes,4-6 others have shown no clear benefit,7,8 thus highlighting ongoing uncertainty in the field.

In this issue of JAMA Neurol ogy, Zhang and colleagues9 report the results of a single-blind, multicenter randomized clinical trial of the effects of exercise and intensive vascular risk reduction on cognitive function. Eligible study participants were between the ages of 60 and 85 years at baseline with a history of hypertension, family history of dementia, or self-reported cognitive decline. The study used a 2 × 2 factorial design wherein participants were randomized to aerobic exercise training alone, intensive pharmacological reduction of cardiovascular risk factors (IRVR) alone, both aerobic exercise and IRVR, or usual care for a 24-month period. The IRVR protocol lowered systolic blood pressure to less than 130 mm Hg, and participants with baseline serum low-density lipoprotein cholesterol (LDL-C) of 70 mg/dL or higher were also treated with a high-intensity statin.

Studying 2 distinct human cohorts with recent exposure to TB

https://doi.org/10.1172/jci.insight.202134 Paul Ogongo & team find different individual Mycobacterium tuberculosis antigens induce distinct T cell responses, with important implications for TB vaccine development.

5Center for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya.

6Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, California, USA.

7Department of Infectious Disease and Immunology, Center for Vaccine Research, Statens Serum Institut, Copenhagen, Denmark.

Graphene ‘leaf tattoo’ sensor tracks plant hydration in real time

Is your houseplant thirsty? Are crops getting enough water? Is a forest at high risk of wildfire? Leaf health can answer all these questions, and researchers at The University of Texas at Austin have developed new technology to measure hydration levels with greater accuracy and without hurting the plant. The researchers developed an electronic tattoo for leaves that uses the hyperflexible and sustainable material graphene to track hydration levels. It sticks on the leaves without harming them, a major improvement over current methods that work only with dead or dried-out leaves or provide indirect measurements.

“Being able to directly measure and monitor the live leaf over time, at the point of photosynthesis, gives us more information to understand the health of our plant ecosystems, whether that’s an individual plant or an entire forest,” said Jean Anne Incorvia, associate professor in the Cockrell School of Engineering’s Chandra Family Department of Electrical and Computer Engineering and one of the leaders on the new research published recently in Nano Letters.

Mutation map reveals how amylin mutations influence type 2 diabetes

Researchers at the Institute for Bioengineering of Catalonia (IBEC) have produced a mutational map showing how mutations in amylin—a hormone that plays a key role in glucose regulation—affect its tendency to form toxic amyloid aggregates in the pancreas. This process is linked to the development of type 2 diabetes. While it was already known that certain mutations could alter this aggregation capacity, understanding of this process was fragmented and based on isolated studies. The research is published in the journal Nature Communications.

“For the first time, we can systematically map how thousands of mutations modulate amylin aggregation, bringing human genetics closer to molecular mechanisms,” says Benedetta Bolognesi, the principal investigator of the Protein Phase Transitions in Health and Disease group at IBEC, who is also the lead author of the study.

“We have created a map that allows us to anticipate the potential impact of these mutations in the population,” adds Marta Badia, a researcher in the same group and first author of the study. “We are not assessing toxicity, but rather the protein’s intrinsic propensity to form fibers. This is a first step, but an extremely necessary one.”

Signal, Speculation, and Standards of Proof in Iatrogenic AD

💬 Editorial: Current evidence supports iatrogenic transmission of cerebral amyloid angiopathy but not AlzheimerDisease; a definitive causal link between contaminated growth hormone exposure and AD remains speculative.

Neurodegenerative diseases caused by protein misfolding (eg, Alzheimer disease [AD], frontotemporal lobar degeneration, Parkinson disease) share many similarities with prion diseases. All demonstrate template-directed protein misfolding and propagation in vivo. However, with 1 exception, they have not exhibited interindividual or zoonotic transmission as observed in iatrogenic Creutzfeldt-Jakob disease and variant Creutzfeldt-Jakob disease, respectively. An important unresolved question is whether other proteinopathies are transmissible between individuals, and if so, their potential impact on public health. To address these concerns, several prion centers have re-assessed cases of iatrogenic Creutzfeldt-Jakob disease due to cadaver-derived human growth hormone (c-hGH) and dura mater grafts. Although amyloid β (Aβ) plaques and cerebral amyloid angiopathy were commonly seen, tau pathology necessary for a diagnosis of AD was not.1,2 Thus, while there is adequate evidence that cerebral amyloid angiopathy may be acquired through iatrogenic mechanisms, iatrogenic transmission of AD pathology remained speculative.3

In 2024, Banerjee et al published an article entitled, “Iatrogenic Alzheimer’s Disease in Recipients of Cadaveric Pituitary-Derived Growth Hormone.”4 This assertion of iatrogenic AD (iAD) was largely predicated on the detection of Aβ seeds contaminating the c-hGH used in 8 recipients who later presented with concerns of cognitive impairment. The recipients had a variety of premorbid neurologic conditions that led to the need for hGH, many of which are themselves associated with later-life neuropathology, perhaps most notably radiotherapy and epilepsy. This report was met with some skepticism, given how the cases were diagnosed and the lack of biological evidence to confirm AD pathology in most participants.5,6

In this issue of JAMA Neurol ogy, the same group presents a report of an autopsy-confirmed case of AD in a c-hGH recipient and describes the clinical phenotype of 3 other c-hGH recipients.7 In their autopsy case, they describe cerebral amyloid angiopathy and high-level AD neuropathologic change (A3B3C3), providing the strongest confirmation of an AD diagnosis in their cohort. Additionally, this individual had limited premorbid medical conditions (complex partial seizures) and required hGH due to idiopathic growth hormone deficiency. They describe the clinical presentation as a mixed primary progressive aphasia phenotype and remark that 3 other c-hGH recipients presented similar primary progressive aphasia phenotypes. One of these was diagnosed with atypical AD due to unspecified single-photon emission computed tomography imaging findings and the other through a reduced Aβ42/40-cerebrospinal fluid ratio.

Eyal Aharoni — Breaking the Moral Turing Test

Dr. discusses one of the most provocative frontiers in technology: the automation of moral judgement — in his talk focusses on outcomes of a comparative moral Turing test (AI outperforms humans across a range of metrics), as well as AI assisted medical triage!

Link in reply🔗

Eyal Aharoni

Dr. Eyal Aharoni (Georgia State University) to the Future Day 2026 stage to discuss one of the most provocative frontiers in technology: the automation of moral judgement.

Breaking the Moral Turing Test: Studies of human attribution and deference to AI moral judgment and decision-making.

Continue reading “Eyal Aharoni — Breaking the Moral Turing Test” | >

/* */